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Abstract
We assessed the impact of new antineoplastic agents on the overall survival (OS) of
advanced non-small cell lung cancer (aNSCLC) patients followed up until 2012. Multivariate
regression models were run for OS (outcome) and four proxies for innovation (exposure):
Index (InnovInd, for SEER-Research data 1973–2012) and three levels of aggregation of
Mean Medication Vintage, i.e. Overall (MMVOverall), using data aggregated at the State
Level (MMVState), and using patient-level data (MMVPatient) using data from the US captured
in SEER-Medicare 1991–2012. We derived Hazard ratios (HR) from Royston-Parmar mod-
els and odds ratios (OR) from a logistic regression on 1-year OS. Including 164,704 patients
(median age 72 years, 56.8% stage IV, 61.8% with no comorbidities, 37.8% with adenocar-
cinoma, 22.9% with squamous-cell, 6.1% were censored). One-year OS improved from
0.22 in 1973 to 0.39 in 2012, in correlation with InnovInd (r = 0.97). Ten new NSCLC drugs
were approved and 28 more used off-label. Regression-models results indicate that thera-
peutic innovation only marginally reduced the risk of dying (HROverall = 0.98 [0.98–0.98],
HRMMV-Patient = 0.98 [0.97–0.98], and HRMMV-State = 0.98 [0.98–0.98], and slightly improved
1-year survival (ORMMV-Overall = 1.05 95%CI [1.04–1.05]). These results were validated with
data from the Swedish National Health Data registers. Until 2013, aNSCLC patients were
treated undifferentiated and the introduction of innovative therapies had statistically signifi-
cant, albeit modest, effects on survival. Most treatments used off-guidelines highlight the
high unmet need; however new advancements in treatment may further improve survival.
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Introduction
Worldwide, lung cancer remains the most commonly occurring malignant neoplasm with 1.8
million new cases in 2012 (12.9% of all new cancer cases), and the most common cause of
death from cancer accounting for 1.6 million lives lost (19.4% of all cancer-related deaths)[1].
In the United States (US), 218,527 new cases were diagnosed in 2015 and 153,718 deaths were
registered. The majority of lung cancers are non-small cell lung cancer (NSCLC) and diag-
nosed when inoperable locally advanced (Stage IIIB) or metastatic (Stage IV)[2–5]. While
5-year survival rates for the overall lung cancer patient population improved almost 60%
between 1975–1977 and 2008–2014, those diagnosed with advanced or metastatic NSCLC
(aNSCLC) still carry very poor prognosis. In the 1970s, the median overall survival for patients
with aNSCLC was six months; and by 2012, it had barely surpassed nine months[6].
Historically, treatment options have been limited[6] and consisted of successive generations
of chemotherapy (anthracyclines, alkylating agents like platinum-based compounds, and tax-
anes) that did not differentiate patients by histology, tumor profile or specific biomarkers[7].
While Lichtenberg and colleagues have proven that pharmaceutical innovation has positively
affected the life expectancy of cancer patients in general[8, 9], the limited effectiveness in
aNSCLC warrants additional research.
Therefore, we conducted a thorough account of the level of therapeutic innovation intro-
duced between 1991 and 2012 in the treatment of patients diagnosed with aNSCLC and an
analysis of its impact on survival.
Materials and methods
This was a retrospective observational cohort study on patients diagnosed with aNSCLC
between 1991 and 2012, in the US, selected according to the following criteria: a primary diag-
nosis of advanced or metastatic NSCLC microscopically-confirmed. Patients were excluded if
they met any of the following criteria: diagnosed at autopsy or within 30 days of death date,
neuroendocrine tumours, younger than 18, or disease stage earlier than IIIA as defined by the
American Joint Committee on Cancer (AJCC) classification.
We extracted patient-level data from the linked database SEER-Medicare (Carrier Claims,
Outpatient Claims and Medicare Provider Analysis and Review and Prescription Drug Event
File)[4]. In order to assess a longer-term trends in survival, we also analyzed two extended
cohorts of patients diagnosed between 1973 and 2012, with data extracted from the SEER
Research database and from the Swedish National Health Data registers (Cancer Register,
Cause of Death Register and Patient Register)[10]. Though no patient-level treatment data was
available for those additional 18 years in either country so only aggregated analyses were
performed.
Additionally, we conducted a targeted literature review in MEDLINE and EMBASE to
gather necessary information on oncology therapies introduced during these years. The review
was complemented with targeted searches in the archives of the US Food and Drug Adminis-
tration (FDA)[11], the European Medicines Agency (EMA)[12], the Swedish Medicinal
Agency (La¨kemedelsverket)[13], and the Clinical Outcome Labelling Claims Database (PRO-
Labels™). These searches aimed at identifying marketing authorizations for treatments
approved in aNSCLC with the respective dates, as well as evidence and date of first use for
treatments without a labelled aNSCLC indication (i.e., off-label).
All methods were carried out in accordance with relevant guidelines and regulations and
the protocols were approved by the respective institutional and/or licensing committee. In the
US, this study was approved by Quorum Review IRB on May 20, 2015 with registration num-
ber 30556/1. In Sweden, this study was approved by the Regionala Etikpro¨vningsna¨mnden in
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available to investigators for research purposes
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Stockholm on March 25, 2015 with registration number 2015/406-31/4. Following the norms
from these authorities, no informed consent from the subjects was required.
Definition of innovation
Following on Lichtenberg’s work, this study defines innovation in oncological treatments in
relation to their year of introduction[14, 15], and builds four proxies. The first proxy is the
Innovation Index (InnovInd), defined as the accumulated sum of aNSCLC systemic treat-
ments available by year of approval, or evidence of earlier off-label use if confirmed in the liter-
ature. This proxy was assembled for the US and for Sweden for the period 1973–2012, and
used to evaluate the long-term trend analysis of aggregated data.
The other three proxies incorporate actual usage to account for speed of uptake of new ther-
apies. Due to the availability of patient-level treatment data, they only cover the period 1991–
2012 in the US. These were defined by the Mean Medication Vintage (MMV) of aNSCLC sys-
temic treatments used per year (i.e., year of introduction weighted by the share of patients
using that given treatment in each year, regardless of treatment line). Further, three levels of
aggregation were used for the MMV: a) MMVoverall: estimated for each cohort defined by the
year of diagnosis, b) MMVstate: clustered geographically by state in each year, and c) MMVpati-
ent: individual-patient level estimates per year.
Statistical analyses
We present descriptive statistics and graphical illustrations of the historical trajectory of expo-
sure, outcomes and main covariates. We measured the correlation between innovation (Inno-
vInd) and overall survival (OS) with the Pearson’s correlation coefficient (r).
We conducted a Cox proportional-hazard (CPH) regression, with survival time in days as
the outcome and innovation in aNSCLC treatments as the exposure. Covariates included in
the models were gender, age of diagnosis, Charlson Comorbidity Index (CCI) (16), histology,
residence and race (US only). Patients who were still alive or lost to follow-up at the end of the
study period were censored. We tested the proportional hazard assumption using Schoenfeld
residuals. If the assumption of proportionality was not fulfilled, to relax the assumption of lin-
earity of log time, we built a Royston-Parmar flexible model [16] by using restricted cubic
splines for those variables at risk. In both cases, we estimated hazard ratios (HR) with 95% CIs
and p-values.
Additionally, we ran a logistic regression using one-year survival as a dichotomous depen-
dent variable with the same exposure proxies and covariates as in the previous models and esti-
mated odds ratios with 95% CIs and p-values.
Results
We extracted the records of 164,704 patients diagnosed between 1991 and 2012 who met the
inclusion and exclusion criteria, of which 60,400 received at least one line of active treatment.
The majority of patients were excluded because NSCLC was a secondary tumor, or they pre-
sented with different histologies (small-cell and neuroendocrine) (Fig 1). The 10,076 (6.12%)
patients who were still alive at the end of follow-up, plus 201 (0.12%) lost to follow-up, were
subject to censoring.
Table 1 presents the main characteristics of the patient population under analysis (SEER
Medicare 1991–2012). The median age was 72 years, ranging between 21 and 104 years old.
The majority of patients were men (56.8%) with metastatic disease (stage IV accounts for
56.8%) and of white race (79.9%). The most common histology was adenocarcinoma, followed
by squamous-cell carcinoma; however, 24.1% of patients had an unconfirmed histology.
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Table 1 also depicts a baseline comparison of patient characteristics with a cohort from the
more representative SEER Research database, selected using the same criteria presented in Fig
1. The main difference is that the population under study is older than overall aNSCLC popu-
lation in the US.
Between 1973 and 2012, median OS increased from five to nine months and 1-year OS rose
from 0.22 to 0.38. Fig 2 reveals that the evolution of 1-year OS is highly correlated with the pro-
gressive introduction of new aNSCLC systemic therapies (r = 0.97); particularly after 1992,
when most of the innovative treatments were introduced into the treatment armamentarium
(Table 2). Between 1991 and 2012, we identified 38 therapies in use for aNSCLC, of which 28
(74%) did not have a labeled indication for aNSCLC. The other 10 therapies had received FDA
approval for aNSCLC, many as part of label expansion. Notably, five of them were already in
use for aNSCLC patients preceding their official indication. Table 2 presents a detailed account
of the year and circumstances of introduction of each drug.
The regression analyses produced consistent results with all three definitions of innovation,
as can been in Table 3. The HR for the exposure MMV was 0.98 (95%CI 0.98–0.98 and 0.97–
0.98 in the MMVpatient regression), indicating that newer, mostly targeted, treatments have
had a beneficial, albeit small, influence on the survival of aNSCLC patients. The logistic regres-
sion of 1-year OS with an OR = 1.05 (95%CI 1.04–1.05) confirms these findings as do the anal-
yses in Sweden with InnovInd 1991–2013 as exposure (Royston-Parmar flexible model with
HR = 0.95 (95% CI 0.94–0.95) and logistic regression model with OR = 1.10 (95% CI 1.09–
1.10)).
Fig 1. Patient selection flow chart, SEERMedicare.
https://doi.org/10.1371/journal.pone.0232669.g001
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The results of the regression analyses also demonstrate that older age, more advanced dis-
ease at diagnosis, male gender, and higher comorbidity burden were significantly associated
with a worse prognosis. As for histology, patients diagnosed with adenocarcinoma had better
prognosis than those with large-cell carcinoma. No statistically significant differences were
found in the survival of adenocarcinoma patients compared with patients diagnosed with
squamous-cell carcinoma; although results of the patient-level exposure (MMVpatient) analysis
did support a negative impact of squamous cell histology on survival. Finally, patients with his-
tology classified as NSCLC or malignant carcinoma had poorer survival.
Table 1. Main characteristics of the patient population and assessment of generalizability.
Patients’ characteristics SEER-Medicare (N = 164,704) SEER Research (N = 133,077)
Gender (male) 93,514 56.8% 76,678 57.6%
Age at diagnosis,mean (SE) 71.5 (0.022) NA 67.0 (0.03) NA
Age at diagnosis,median (max; min) 72 (21; 104) NA 68 (18; 104) NA
State of residence
California 58,949 35.8% 19,565 14.7%
Connecticut 11,147 6.8% 21,248 16.0%
Georgia 16,006 9.7% 11,508 8.6%
Hawaii 3,428 2.1% 6,248 4.7%
Iowa 10,080 6.1% 17,350 13.0%
Michigan 13,979 8.5% 25,917 19.5%
NewMexico 3,337 2.0% 6,755 5.1%
Utah 2,033 1.2% 4,082 3.1%
Washington 11,061 6.7% 20,404 15.3%
Kentucky 10,841 6.6% NA NA
Louisiana 8,912 5.4% NA NA
New Jersey 14,931 9.1% NA NA
Race
White 131,590 79.9% 105,747 79.5%
Black 18,458 11.2% 16,374 12.3%
Asian 8,680 5.3% 7,043 5.3%
Other 5,976 3.6% 3,891 3.0%
Histology
Adenocarcinoma 62,182 37.8% 50,083 37.6%
Squamous 37,707 22.9% 29,227 22.0%
Malignant carcinomas (NOS) 12,604 7.7% 14,428 10.8%
NSCLC 27,017 16.4% 16,081 12.1%
Large cell carcinoma 8,288 5.0% 8,055 6.1%
Other 16,906 10.3% 15,203 11.4%
AJCC Stage (7th edition)
IIIA 25,488 15.5% 14,613 11.0%
IIIB 45,722 27.8% 28,386 21.3%
IV 93,494 56.8% 65,650 49.3%
Not staged 0 0.0% 24,428 18.4%
Charlson Comorbidity Index,mean (SE) 0.71 (0.03) NA NA NA
SEER = Surveillance, Epidemiology, and End Results, NOS = Not Otherwise Specified; SE = Standard Error; NA = Not Available or Not Applicable; NSCLC = Non-
Small Cell Lung Cancer; AJCC = American Joint Committee on Cancer
https://doi.org/10.1371/journal.pone.0232669.t001
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To provide context for the interpretation of these findings, in Fig 3 shows the historical tra-
jectory of the main co-variates. During the study period, the mean age of patients increased as
did the percentage of women. Progressively more patients presented with metastatic disease
(Stage IV) and fewer were not staged. The histology composition of the cohorts under study in
the US varied significantly. At the beginning of the period, squamous-cell carcinoma was the
most frequent but as of the early 1990s, more patients were diagnosed with adenocarcinoma.
We can also see a shift of Not Otherwise Specified (reduction) and NSCLC (increase) around
2001, indicating a change in classification.
Discussion
In our study, we established that US patients diagnosed with aNSCLC presented with poor
prognosis (9-month median OS), and, despite improvements in one-year OS survival from
14% in 1973, only 39% of patients would survive longer than one year by 2012. During the 40
years between 1973 and 2012, the FDA approved only 10 new systemic therapies for NSCLC
with minimal differentiation across subpopulations. The urgent attempts of treating physicians
to offer alternatives to their patients is reflected by the off-label use of 28 agents. The reasons
for use without an official indication depicts the severity of aNSCLC and the limited treatment
options within this disease.
Finding effective treatments for these patients proved particularly arduous due to the het-
erogeneous nature of NSCLC from a clinical, histological, molecular and biological standpoint
[17] as well as the extremely high somatic mutation frequency [18]. A brief review in the Regis-
try and Results Database ClinicalTrials.gov revealed a large number of, thus far, unsuccessful
Fig 2. Innovation index and 1-year overall survival over time in the USA.
https://doi.org/10.1371/journal.pone.0232669.g002
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Table 2. Data used in the construction of the mean medication vintage proxy variables.
Active substance FDA approval (primary
indication)
FDA approval (in
NSCLC)
Date of first use in
Medicare
Number of treatments found in
Medicare 1991–2013
First use for
NSCLC
Type of
evidence
5-Fluorouracil 1962 1991-01-16 1,474 1973 Off-label
Cyclophosphamide 1959 1991-01-10 516 1973 Off-label
Methotrexat 1953 Not mentioned 1991-01-03 2,015 1973 Off-label
Vinblastine Sulfate 1965 1991-01-24 1,098 1973 Off-label
Vincristine 1963 1991-03-08 349 1973 Off-label
Doxorubicin
hydrochloride
1974 1991-02-20 466 1974 Off-label
Cisplatin 1978 1991-02-04 8,556 1978 Off-label
Mitomycin 1981 1991-02-07 1,065 1981 Off-label
Etoposide phosphate 1983 1991-02-22 6,251 1983 Off-label
Ifosfamide 1988 1991-03-19 160 1988 Off-label
Carboplatin 1989 no year (NCI) 1991-01-24 51,680 1989 Off-label
Mechlorethamine
Hydrochloride
1949 no year (NCI) 1993-03-01 33 1993 Off-label
Mercaptopurine 1953 2007-01-03 34 1993 Off-label
Fludarabine 1991 1994-03-14 40 1994 Off-label
Paclitaxel 1992 1998-06-30 1994-01-03 35,056 1994 Earlier off-
label
Vinorelbine tartrate 1994 1994-12-23 1995-03-03 11,317 1994 FDA
approval
Docetaxel 1996 1999-12-23 1996-11-22 16,331 1996 Earlier off-
label
Irinotecan Hydrochloride 1996 1998-04-10 937 1996 Off-label
Topotecan hydrochloride 1996 1998-01-08 348 1996 Off-label
Gemcitabine 1996 1998-08-25 1997-03-21 20,891 1997 Earlier off-
label
Porfimer sodium 1995 1998-01-09 1998-04-14 20 1998 FDA
approval
Rituximab 1997 2000-03-01 137 2000 Off-label
Trastuzumab 1998 2000-01-12 50 2000 Off-label
Gefitinib 2003 2003-05-05 2006-09-27 73 2003 FDA
approval
Oxaliplatin 2002 2003-08-11 84 2003 Off-label
Bevacizumab 2004 2006-10-11 2004-09-07 8,399 2004 Earlier off-
label
Bortezomib 2003 2004-07-26 21 2004 Off-label
Cetuximab 2004 2004-07-29 452 2004 Off-label
Erlotinib 2004 2004-11-18 2007-01-01 9,502 2004 FDA
approval
Pemetrexed disodium 2004 2004-08-19 2004-05-18 13,437 2004 Earlier off-
label
Azacitidine 2004 2006-02-01 22 2006 Off-label
Anagrelide 1997 2007-04-06 17 2007 Off-label
Celecoxib 1998 2007-01-01 3,257 2007 Off-label
Hydroxyurea 1967 2007-01-02 109 2007 Off-label
Sunitinib Malate 2006 2007-07-03 17 2007 Off-label
Crizotinib 2011 2011-08-26 2011-09-08 78 2011 FDA
approval
Ziv-Aflibercept 2012 2012-07-06 17 2012 Off-label
FDA = Food and Drug Administration, NSCLC = Non-Small Cell Lung Cancer
https://doi.org/10.1371/journal.pone.0232669.t002
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clinical-development programs in aNSCLC. Until recently, much of the efforts devoted to
innovate in this indication resulted fruitless. Yet, the shift in focus in aNSCLC clinical develop-
ment that followed including the creation of a comprehensive catalogue of the somatic muta-
tions responsible for initiation and progression of lung cancer [19], paired with the emergence
of immunooncology therapies may be turning the tide. During the past 10 years, we have
gained transformative insights into the molecular pathways that play a determinant role in
tumor cell growth and proliferation in NSCLC [20], and the consequential advances in clinical
and translational research resulted in the approval of 15 new innovative therapies by FDA
since 2012 alone. These are dramatically transforming the management of NSCLC. While
some new therapies aim to treat the overall aNSCLC indication (like ramucirumab), most of
Table 3. Regression models with alternative definitions of innovation and survival.
Covariates R-PFMMMV (overall) R-PFMMMV (patient level) R-PFMMMV (clustered per
state)
Logistic regression MMV
(overall)
(N = 164,704) (N = 60,125) (N = 164,704) (N = 164,704)
HR P>|z| 95% CI HR P>|z| 95% CI HR P>|z| 95% CI OR P>|z| 95% CI
Innovation 0.98 0 0.98 0.98 0.98 0 0.97 0.98 0.98 0 0.98 0.98 1.05 0 1.04 1.05
Age at diagnosis 1.03 0 1.03 1.04 1.03 0 1.03 1.03 1.03 0 1.03 1.04 0.94 0 0.94 0.94
CCI� 1.12 0 1.11 1.12 1.13 0 1.12 1.14 1.12 0 1.11 1.12 0.81 0 0.80 0.82
Gender: (ref: Female)
Male 1.19 0 1.18 1.20 1.25 0 1.22 1.27 1.19 0 1.18 1.20 0.72 0 0.70 0.73
Race (ref: White)
Asian 0.82 0 0.81 0.84 0.84 0 0.80 0.87 0.82 0 0.81 0.84 1.41 0 1.34 1.49
Other 0.93 0 0.90 0.97 0.87 0 0.81 0.94 0.93 0 0.90 0.97 1.14 0 1.07 1.22
Black 1.05 0 1.03 1.07 0.90 0 0.87 0.94 1.05 0 1.03 1.07 0.93 0 0.90 0.97
State of residence (ref: California)
Connecticut 0.92 0 0.90 0.95 0.99 0.53 0.95 1.03 0.92 0 0.90 0.95 1.12 0 1.07 1.17
Georgia 1.00 0.78 0.98 1.03 1.14 0 1.10 1.18 0.99 0.45 0.97 1.01 0.96 0.083 0.93 1.00
Hawaii 1.08 0 1.03 1.13 0.96 0.34 0.89 1.04 1.11 0 1.06 1.16 0.88 0.003 0.81 0.96
Iowa 1.01 0.52 0.98 1.04 1.10 0 1.06 1.14 0.99 0.62 0.97 1.02 0.96 0.146 0.92 1.01
Michigan 0.95 0 0.94 0.97 1.05 0 1.02 1.08 0.93 0 0.91 0.94 1.04 0.05 1.00 1.09
NewMexico 1.07 0 1.04 1.11 1.06 0.07 0.99 1.13 1.06 0 1.02 1.10 0.84 0 0.77 0.91
Utah 1.06 0.02 1.01 1.11 1.06 0.14 0.98 1.15 1.03 0.21 0.98 1.08 0.90 0.039 0.81 0.99
Washington 0.92 0 0.90 0.94 1.01 0.78 0.96 1.05 0.92 0 0.89 0.94 1.02 0.449 0.97 1.07
Kentucky�� 1.08 0 1.06 1.10 1.18 0 1.13 1.23 1.05 0 1.03 1.08 0.82 0 0.78 0.86
Louisiana�� 1.09 0 1.06 1.11 1.19 0 1.14 1.24 1.08 0 1.05 1.10 0.81 0 0.77 0.85
New Jersey�� 0.95 0 0.93 0.97 0.99 0.52 0.95 1.02 0.95 0 0.92 0.97 1.09 0 1.05 1.14
Histology (ref: Adenocarcinoma)
Large cell carcinoma 1.19 0 1.16 1.22 1.21 0 1.15 1.26 1.19 0 1.16 1.23 0.68 0 0.64 0.72
Malignant carcinoma (NOS) 1.24 0 1.21 1.26 1.22 0 1.18 1.27 1.24 0 1.21 1.27 0.64 0 0.61 0.67
NSCLC 1.12 0 1.11 1.14 1.15 0 1.12 1.18 1.12 0 1.11 1.14 0.76 0 0.73 0.78
Other 0.92 0 0.90 0.94 0.89 0 0.87 0.92 0.92 0 0.90 0.94 1.14 0 1.10 1.19
Squamous 0.99 0.54 0.98 1.01 1.04 0 1.02 1.07 0.99 0.54 0.98 1.01 0.89 0 0.86 0.91
AJCC Stage (ref: IIIA)
IIIB 1.72 0.00 1.67 1.76 1.59 0 1.53 1.66 1.72 0 1.67 1.76 0.55 0 0.53 0.56
IV 2.85 0.00 2.78 2.92 2.62 0 2.53 2.72 2.85 0 2.78 2.92 0.23 0 0.22 0.24
� R-PFM = Royston-Parmar flexible model; MMV =Mean Medication Vintage; HR = Hazard Ratio, CI = Confidence Interval, CCI = Charlson Comorbidity Index;
NOS = Not Otherwise Specified; AJCC = American Joint Committee on Cancer
https://doi.org/10.1371/journal.pone.0232669.t003
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them target subpopulations pre-defined by histology (like necitumumab for squamous-cell
and pemetrexed for non-squamous types) or specific markers with the potential to enhance
efficacy [20]. The most commonly tested and established biomarkers (and respective thera-
pies/inhibitors) in this indication include Epidermal Growth Factor Receptor (afatinib, gefiti-
nib, and osimertinib), Anaplastic Lymphoma Kinase (alectinib, brigatinib, ceritinib, and
crizotinib) and Programmed Death-Ligand 1 (atezolizumab, nivolumab, and pembrolizumab).
New targets continue to emerge, such as BRAF mutations (dabrafenib and trametinib) or the
ROS1-gene targeted by crizotinib. Numerous meta-analyses have investigated the expected
benefits for patients managed with these treatments showing significant gains in progression-
free survival [21–27] and impact on OS being currently investigated.
For our study, the 4-month gain in median survival delivered by the 10 new therapies over
four decades (and 28 more used off-label) seems low when compared with the threshold of at
least a 3.25- to 4-month gain as a measure of meaningful improvement of a new therapy over
standard of care recommended by the American Society of Clinical Oncology (ASCO) [28].
The effect of innovation on the expected survival of patients with aNSCLC, during the study
period, was also modest (adjusted HR = 0.98), if compared with the target HR for a new ther-
apy recommended by ASCO (HR between 0.76 and 0.8 for squamous and non-squamous
respectively) [28]. Although our study showed a high correlation between InnovInd and OS,
the small improvement observed in OS, in comparison with ASCO recommendations, may
have been impacted by the lower baseline OS at the beginning of our study (14% one-year OS
in 1973).
We validated these results through the analysis of Swedish data, specific to the survival out-
comes as well as the evolution of patients’ characteristics over time. The proportion of females
diagnosed with aNSCLC significantly increased in both countries, which may be the result of
gender changes in smoking habits. Prevalence of smoking among women grew steadily follow-
ingWorldWar II, and continued to increase even while the trend among men has been declin-
ing since the 1970’s [7, 29]. Similarly, the proportion of patients diagnosed with different
Fig 3. Evolution of patient characteristics over time.
https://doi.org/10.1371/journal.pone.0232669.g003
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histological types has changed over time with fewer cases of squamous-cell carcinoma, poten-
tially reflecting the shift to low tar and nicotine cigarettes [30]. One of the pitfalls of analyzing
aggregate results of patient-level data over a 20-year period may be that the impact of innova-
tion on small subgroups of patients who have achieved greatest benefit could have been diluted
in the aggregate analysis. Thus, our aggregated long-term analysis may be masking higher
improvement in the 1-year OS of patients diagnosed with adenocarcinoma as compared to
those with squamous-cell carcinoma, as demonstrated by Olszewski et al. [31].
An important strength of our study is the use of data from national population-based regis-
tries in both countries, which grants these analyses external validity and provides the frame-
work for a natural experiment given the differences in healthcare systems and settings along
the entire continuum of care between the US and Sweden and across smaller administrative
units (states in the US). Additionally, in this study, we provide a thorough accounting for
actual uptake of innovative medicines, even those initially indicated for different cancers and
used off-label.
However, a few limitations grant the careful interpretation of the study results. When we
evaluated the association between new systemic anti-cancer treatments and outcomes, we con-
trolled for as many potential confounders as possible (age at diagnosis, comorbidities, sex, and
disease severity), but data on other important prognostic variables such as performance status
were not available. Furthermore, other unaccounted factors such as advances in screening, the
precision of diagnostics to detect distant metastases and the overall organization of the treat-
ment continuum may also have influenced the results. Lastly, in the US roughly 60% of the
patients have Medicare Part D coverage, including prescription of drugs, and only these drugs
are found in SEER-Medicare. Thus, it is possible that we have underestimated the number of
treatments, though it is difficult to predict how a shift in the treatment mix may have influ-
enced the analyses. Finally, lack of complete patient-level treatment data, which if consistently
collected across the whole study period, would have enabled us to construct a stronger proxy
variable to define innovation.
Our analysis of the US SEERMedicare and Swedish cohorts shows that the outlook for
aNSCLC patients by the end of 2012 was not optimistic. Yet, the pace at which innovation is
being introduced in this indication is accelerating as reflected by the fact that FDA approved
ten new chemotherapies in the 40 years before 2012, and 15 new oncology treatments in the
five years that followed. Furthermore, the promising initial results of innovative immunothera-
pies and novel targeted agents suggests that we may be on the brink of a shift in that trajectory
and a long-awaited transformational impact on the survival of aNSCLC patients.
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